Chirantan Chatterjee joins the Indian School of Business as an assistant professor in economics and public policy in April 2017. He will also be affiliated as a Max Research Fellow in Healthcare and Bharti Research Fellow in Public Policy at ISB’s Mohali campus. Between 2011 and March 2016 Chatterjee was a faculty member with IIM Bangalore where he earlier held the Young Faculty Research Chair. Chatterjee earned a Ph.D. & an M.Phil. in public policy and management from the Carnegie Mellon University. He has a B.Tech. in civil engineering from the Indian Institute of Technology, Roorkee and a MBA from the Indian Institute of Management, Calcutta. Between 2003 & 2005, after his MBA, Chatterjee worked as a business journalist covering corporate innovation for The Economic Times, India.
Chatterjee’s research employs insights from empirical industrial organization, applied microeconomics and strategic foundations of industries, to examine the tradeoffs between access, innovation and welfare in global pharmaceutical & healthcare markets. His work is published in global peer- reviewed outlets like the RAND Journal of Economics, Journal of Health Economics, The Journal of Law & Economics (forthcoming), Research Policy (forthcoming), Social Science & Medicine, Health Policy and Planning, Economic and Political Weekly, Journal of Antitrust Enforcement (forthcoming), Brookings Press and NBER. His dissertation work on the economics of innovation and IP in the global pharmaceutical industry was supported by the National Science Foundation, and in 2015 his research was cited on the NSF Science of Science Policy website. In the past Chatterjee’s research has also been supported by Pfizer’s International Policy Unit. Some of his current research under review explore the incentives for innovation in Indian vaccine markets given health shocks like pandemics, the role of behavioral biases in emerging world demand for pharmaceutical (and other) fairness creams, the market impact of pharmaceutical relabeling in the US and the role of regulatory interventions like Orphan Drug Act in facilitating efficient investor-investee matches in bio-pharmaceutical entrepreneurship.
Chatterjee has also been invited for research seminars at universities around the world including UC Berkeley, Stanford University (Hoover IP2 conference), University of Pennsylvania, NBER Summer Institute & Productivity Meetings, the 2016 Lifesciences Symposium by Bates & White, Georgia Institute of Technology, London Business School, National University of Singapore, Peking University HSBC Business School and Indian Statistical Institute, Delhi. Chatterjee has also consulted for the World Bank (on Universal Healthcare Coverage in India) & Competition Commission of the Government of India (on Indian pharmaceutical markets). His inputs were cited by the NITI Aayog, India’s central planning authority in a 2015 report on innovation and entrepreneurship policy for the economy.
He is actively involved in executive education with healthcare executives and leaders and has in the past conducted programs as faculty director with Johnson & Johnson (on Indian hospital markets), with Novartis (on women healthcare leaders in India), with Novo Nordisk (on Indian pharmaceutical industry & health economics) and with Wockhardt, Jubilant, & Micro-Labs on (growth strategies and managerial economics). In 2015, Chatterjee conceptualized and chaired the 1st India Conference on Innovation, Intellectual Property & Competition, a first of its kind international innovation policy conference in India supported by Qualcomm Inc. & Tata Trusts. His deep passion about Indian healthcare markets and for democratizing education has also resulted in the first ever MOOC on healthcare markets in India in 2016 available through edX.